Sabrina McCrear

988 crisis centers face staffing and funding challenges despite rising demand, raising concerns about long-term sustainability.

At the IVBM Charlotte event, Seungjean Chai, MD, emphasized that patient-centered design, guidelines, and subspecialty expertise are essential to high-value oncology care.

Experts discussed value-based oncology care, CAR T-cell therapy access gaps, myeloma advances, and bispecific therapy challenges.

Experts examined oncology care innovation, access gaps to CAR T-cell therapy, advances in myeloma care, and partnerships in value-based care.

Kaitlyn Schomberg, PharmD, discusses BiTE therapy adoption, toxicity management, and care coordination in community oncology settings.

Wastewater SARS-CoV-2 levels correlated with hospital COVID-19 cases, supporting targeted screening of asymptomatic patients.

CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization challenges remain, per Sylvester Homsy, MD.

Justin Favaro, MD, discusses independent oncology models, ACA challenges, and strategies to reduce health care costs at IVBM Charlotte 2026.

RSV vaccines and nirsevimab are linked to reduced infant hospitalizations, though seasonal spikes and data limitations remain concerns.

Phase 3 TETON-1 trial shows inhaled treprostinil improves FVC in IPF, signaling a potential new antifibrotic option.

Explore 5 FAQs on CDC opioid guidelines, including dosing, tapering, monitoring, and managed care strategies to reduce overdose risk.

AMCP 2026 spotlighted oncology innovation, AI, and payer strategies, with KOL insights on cost, access, and evolving managed care trends.

OUD diagnoses have declined, but use of medication to treat OUD has increased among Medicaid beneficiaries, highlighting policy gains and ongoing state-level disparities.

Black Maternal Health Week spotlights disparities, Medicaid postpartum coverage gains, and ongoing policy efforts to reduce maternal mortality.

TETON-1 data show inhaled treprostinil improves FVC and reduces worsening in IPF, supporting a potential new treatment and combo strategy.

Experts from AMCP emphasize the importance of drug-adjacent early detection tests and screening ability to improve patient outcomes.

Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending.

Daryl Pritchard, PhD, discusses the challenges to implementing biomarker testing that would advance precision medicine and improve patient outcomes in oncology.

At AMCP 2026, Kelsea Aragon, PharmD, discussed PrEP coverage, long-acting injectables, and payer strategies to improve HIV treatment access and adherence.

Patty Taddei-Allen, PharmD, MBA, examines how co-pay accumulators, maximizers, and AFPs shift costs, impact rebates, and create access challenges for patients.

At AMCP 2026, Adam Colborn, JD, warns the Alternatives to PAIN Act may expand access but risk destabilizing Medicare Part D and limiting plan participation.

Abby Kim, PharmD, delves into oncology trends, biomarker testing gaps, and evolving clinical pathways shaping precision care and treatment decisions.

Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity treatment access.

At AMCP 2026, Daryl Pritchard, PhD, highlighted fragmentation, evidence gaps, and decision support needs limiting precision medicine adoption and outcomes.

Kelsea Aragon, PharmD, highlights the role of long-acting HIV therapies like lenacapavir and cabotegravir in improving adherence, flexibility, and prevention access.

Patty Taddei-Allen, PharmD, MBA, warns that co-pay accumulators and maximizers may lower plan costs but increase patient burden and disrupt medication adherence.

Adam Colburn, JD, highlights 3 federal bills to expand value-based care, digital therapeutics, and pharmacist reimbursement across Medicare and Medicaid.

Phase 3 CANOPY data show pemivibart safely prevented COVID-19 in patients with CLL, supporting EUA use for immunocompromised populations.

Manufacturer-sponsored biologic coupons have decreased since 2018, with rising per-claim values, impacting patient costs and formulary incentives.

Social determinants of health can delay access to NGS, limiting targeted therapy use and survival outcomes in advanced cancers.